Postdoctoral Training Fellow, Target and E3 Ligase Discovery, Biology, CPD

Due to the high volumes of applications we receive, we reserve the right to close the advert before the published closing date once we have received a sufficient number of applications.  Therefore we advise that you submit your application as early as possible.

Key Requirements

This position is suitable for a strong team player passionate about innovative solutions for cancer drug discovery. They must have a PhD and should have a solid background in cancer cell and molecular biology, and hands-on experience in cell biology and in vitro genetic manipulation techniques applicable for target validation and interrogation of cell signalling pathways. Experience in targeted protein degradation, biochemical and pharmacology assays would be an additional advantage.

Department/Directorate Information:

This position will be based in the ICR Centre for Protein Degradation - a part of the ICR Centre for Cancer Drug Discovery (CCDD) specialising in developing novel drug modalities that re-wire tumour cells' signaling by targeted degradation of key oncogenic drivers. Our experienced biologists work closely with medicinal chemists, biophysicists, computational scientists and oncology specialists on expanding the repertoire of novel degradable drug targets and E3 ligases (enzymes that mediate protein degradation), identifying drugs using innovative screening platforms and characterising their mechanisms of action. Our research provides a nucleus for other teams internally and externally to explore the therapeutic potential of targeted protein degradation medicines. Together with the ICR academics, ICR CCDD and collaborations with pharmaceutical industry we develop these rapidly from the laboratory hypothesis-testing  to early clinical trials, for the benefit of cancer patients.

We encourage all applicants to look at the attached job pack for more detailed information about this role. For an informal discussion about the role please feel free to contact Dr Agnieszka Konopacka, Group Leader, Induced Proximity Therapeutics, Centre for Protein Degradation, via email: [email protected]